Clinical trials often unregistered, unpublished

September 11, 2017

An analysis of more than 100 clinical trials found that they were often unregistered, unpublished and had discrepancies in the reporting of primary outcomes, according to a study published by JAMA. The study is being released to coincide with its presentation at the Eighth International Congress on Peer Review and Scientific Publication.

A major aim of trial registration is to help identify and deter the selective reporting of outcomes based on the results. However, it is unclear whether registered outcomes accurately reflect the trial protocol and whether registration improves the reporting of primary outcomes in publications. An-Wen Chan, M.D., D.Phil., of the Women's College Research Institute, University of Toronto, and colleagues examined adherence to trial registration and its association with subsequent publication and reporting of primary outcomes in 113 clinical trial protocols approved in 2007 by the research ethics committee for the region of Helsinki and Uusimaa, Finland.

Among the trials, 61 percent were prospectively registered (defined as within one month after the trial start date to allow for incomplete start dates and processing delays in the registry) and 57 percent were published. A primary outcome was not defined in 20 percent. Discrepancies between the protocol and publication were more common in unregistered trials (55 percent) than registered trials (6 percent). Discrepancies were defined as (1) a new primary outcome being reported that was not specified as primary in the protocol; or (2) a protocol-defined primary outcome being omitted or downgraded (reported as secondary or unspecified) in the registry or publication.

Prospective registration was significantly associated with subsequent publication (68 percent of registered trials vs 39 percent of unregistered trials). Registered trials were also significantly more likely than unregistered trials to be subsequently published with the same primary outcomes as defined in the protocol (64 percent of registered trials vs 25 percent of unregistered trials).

Limitations of the study include the unclear generalizability beyond the Finnish jurisdiction and the limited sample size.

"Journal editors, regulators, research ethics committees, funders, and sponsors should implement policies mandating prospective registration for all clinical trials. Only with accessible, complete information can interventions be adequately evaluated for patient care," the authors write.
-end-
For more details and to read the full study, please visit the For The Media website.

(doi:10.1001/jama.2017.13001)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2017.13001

The JAMA Network Journals

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.